Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC

Overview of attention for article published in Frontiers in Public Health, August 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 10 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 5,130 followers.

New Research: Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC: Background and objective Sintilimab has superior… https://t.co/gezUpKFIqO #PublicH

09 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.